- Home
- MRVL vs MRK Comparison
MRVL vs MRK Comparison
Compare MRVL & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRVL | MRK |
|---|---|---|
| Founded | 1995 | 2000 |
| Country | United States | United States |
| Employees | 7480 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.1B | 281.2B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | MRVL | MRK |
|---|---|---|
| Price | $266.67 | $127.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 32 | 17 |
| Target Price | $120.28 | ★ $125.59 |
| AVG Volume (30 Days) | ★ 59.5M | 8.6M |
| Earning Date | 05-28-2026 | 04-30-2026 |
| Dividend Yield | 0.15% | ★ 3.06% |
| EPS Growth | ★ 400.98 | 8.01 |
| EPS | ★ 0.04 | N/A |
| Revenue | $8,194,600,000.00 | ★ $65,011,000,000.00 |
| Revenue This Year | $35.14 | $3.61 |
| Revenue Next Year | N/A | $5.41 |
| P/E Ratio | $7,021.25 | ★ N/A |
| Revenue Growth | ★ 42.09 | 1.31 |
| 52 Week Low | $61.44 | $76.66 |
| 52 Week High | $329.88 | $125.96 |
Technical Indicators
Market Signals| Indicator | MRVL | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 52.21 | 70.38 |
| Support Level | $78.57 | $112.68 |
| Resistance Level | $327.04 | N/A |
| Average True Range (ATR) | 24.89 | 3.07 |
| MACD | -6.01 | 0.91 |
| Stochastic Oscillator | 24.95 | 97.44 |
Price Performance
Historical ComparisonAbout MRVL Marvell Technology Inc.
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).